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. Wang).Abstract CC chemokine receptor 4 (CCR4) is a kind of G-protein-coupled receptor, which plays a
pivotal role in allergic inﬂammation. The interaction between 2-(2-(4-chloro-phenyl)-5-{[(naphthalen-1-
ylmethyl)-carbamoyl]-methyl}-4-oxo-thiazolidin-3-yl)-N-(3-morpholin-4-yl-propyl)-acetamide (S009) and
the N-terminal extracellular tail (ML40) of CCR4 has been validated to be high afﬁnity by capillary zone
electrophoresis (CZE). The S009 is a known CCR4 antagonist. Now, a series of new thiourea derivatives
have been synthesized. Compared with positive control S009, they were screened using ML40 as target by
CZE to ﬁnd some new drugs for allergic inﬂammation diseases. The synthesized compounds XJH-5,
XJH-4, XJH-17 and XJH-1 displayed the interaction with ML40, but XJH-9, XJH-10, XJH-11, XJH-12,
XJH-13, XJH-14, XJH-3, XJH-8, XJH-6, XJH-7, XJH-15, XJH-16 and XJH-2 did not bind to ML40.
Both qualiﬁcation and quantiﬁcation characterizations of the binding were determined. The afﬁnity of the
four compounds was valued by the binding constant, which was similar with the results of chemotactic
experiments. The established CEZ method is capable of sensitive and fast screening for a series of lactam
analogs in the drug discovery for allergic inﬂammation diseases.
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1. Introduction
Allergic inﬂammation diseases, such as asthma and atopic
dermatitis, are Th2 lymphocyte-dominant inﬂammatory dis-
ease. CCR4 and its ligands play a role in Th2-type CD4þ T
lymphocyte mediated inﬂammation [1–4]. CCR4 belongs to a
family of CC chemokine receptors, which is a G-protein-
coupled receptor with a characteristic seven-transmembrane
structure. Current treatments for allergic inﬂammation include
antihistamines and bronchodilators, which control symptoms
but not disease progression. In addition, although corticoster-
oids speciﬁcally target the disease, its long-term use can cause
Screening of chemokine receptor CCR4 antagonists by CZE 265steroid resistance and side effects. Other safe and effective
novel therapies for these diseases have been explored [5–7].
Several approaches are being developed to block the effects of
chemokines, including small-molecule antagonists of chemo-
kine receptors, modiﬁed chemokines and antibodies directed
against chemokine receptors. Lactam analog, i.e. 2-(2-(2,4-
dichloro-phenyl)-4-{[(2-methyl-3-chloro-phenyl)-1-ylmethyl]-
carbamoyl}-methyl)-5-oxo-pyrrole-1-yl)-N-(3-piperidinyl-pro-
pyl)-acetamide (S009), as a novel antagonist of CCR4, displays
high CCR4 binding afﬁnity, excellent chemotaxis inhibitory
activity and selectivity toward CCR4 [8]. Previous studies have
been demonstrated that the amino termini of chemokine recep-
tors are important in ligand-binding using the cell-based binding
assays or multidimensional heteronuclear NMR spectroscopy,
such as the interactions of CCR4 agonists, stromal cell-derived
factor-1, eotaxin, interleukin-8, fractalkine and monocyte che-
motactic protein-1 with the amino terminus of their cognate
receptors, with high binding afﬁnities, respectively [9–14].
Recently, we have reported that S009 as a potent antagonist of
CCR4 has a high afﬁnity with the N-terminal extracellular and
both qualiﬁcation and quantiﬁcation characterizations of the
binding were determined [15]. We envisaged that the basic
pharmacophore for CCR4 binding of such compounds consisted
of two wings attached to a central core in a deﬁned conﬁguration
[9,16]. So our arrangement presented took place in these
positions for favorable interactions. For these analogs, we screen
them preliminarily using CZE ﬁrst. Through this experiment, we
hope to ﬁnd other activity compounds and make preparations
for further cell and animal experiments in the drug discovery for
allergic inﬂammation diseases.2. Experimental
2.1. Apparatus and CE conditions
All experiments were performed on a Beckman P/ACETMMDQ
system (Beckman Coulter, Inc., Fullerton, CA, USA) equipped
with a photodiode array detector as well as the 32 KaratTM
software version 5.0 (Beckman). A capillary (Yongnian Optical
Fibre Corp., Hebei, China) with an internal diameter of 75 mm
was used. The total and effective lengths of the capillary were
30.2 cm and 10 cm, respectively. Before using, the new capillaries
were rinsed with 0.1 M NaOH solution for 20 min, and subse-
quently with deionized water for 5 min.
2.2. Chemicals and materials
All chemicals were of analytical grade unless otherwise indicated.
Tris base (ultrapure) and acetic acid used in this study were from
Beijing Chemical Reagent Factory (Beijing, China). These analogs
(Table 1), which are XJH-1, XJH-2, XJH-3, XJH-4, XJH-5,
XJH-6, XJH-7, XJH-8, XJH-9, XJH-10, XJH-11, XJH-12,
XJH-13, XJH-14, XJH-15, XJH-16 and XJH-17, were synthesized
in Professor Song Li’ laboratory (Laboratory of Computer-Aided
Drug Design & Discovery, Beijing Institute of Pharmacology and
Toxicology, 27 Taiping Road, Beijing 100850, China) and
structure was identiﬁed by MS and NMR. It was dissolved in
dimethyl sulfoxide and diluted to the concentration of 1 mM by
phosphate buffered saline (PBS). The equivalent peptide derived
from ML40 was synthetized from Chinese Peptide Company in
Hangzhou, China, and subsequently puriﬁed (purityZ95%)and characterized by reversed-phase high performance liquid
chromatography and mass spectrometry. The synthetized amino
acid sequence of the human CCR4 amino terminus was
MNPTDIADTTLDESIYSNYYLYESIPKPCTKEGIKAFGEL.
Deionized water was used to prepare buffer solutions and
prepared using a Millipore Milli Q-Plus system (Millipore, Bed-
ford, MA). All buffers and solutions used in the study were ﬁltered
through 0.45 mm membranes (Agilent, Germany) before using.
2.3. Sample preparation
To investigate the interactions between the N-terminal extra-
cellular tail of CCR4 and these analogs, different concentrations
of the N-terminal extracellular tail of CCR4 (0 mM, 0.013 mM,
0.04 mM, 0.07 mM and 0.12 mM) were tested for the formation
of complex, which was formed by mixing the analogs with the
N-terminal extracellular tail of CCR4 in the running buffer. It
was incubated for 20 min at 37 1C before CE analysis.
2.4. CZE conditions
To study the interactions between the N-terminal extracellular
tail of CCR4 and these analogs, the temperatures of the
cartridge and sample room were kept at 25 1C and 4 1C,
respectively. Before each measurement, the capillary was
rinsed with running buffer (30 mM Tris–HAc, pH 7.30).
Samples containing the mixtures of the N-terminal extracel-
lular tail of CCR4 and these analogs were injected using the
pressure injection mode at 0.5 p.s.i. for 10 s (1 p.s.i.¼6894.76 Pa).
The applied voltage was 10 kV. The capillary was washed
between runs with the running buffer for 5 min at 20 p.s.i. Each
concentration was run in duplicate.
2.5. Quantitative model for the binding study
In the binding studies, the binding constant and stoichiometry
are important parameters to be determined. Scatchard analysis
is a common way to linearize the binding data, as expressed in
the following equation:
r=Cf ¼Krþ nK ð1Þ
where r is the ratio of the concentrations of the bound ligand
(or receptor) to the total receptor (or ligand) and Cf is the
unbound ligand (or receptor) concentration. K is the apparent
binding constant and n is the number of binding sites [17]. In
this study, r is the concentration ratio of the bound compound
A to the total standard N-terminal extracellular tail of CCR4
and Cf is the free compound A concentration.3. Results and discussion
3.1. Preliminary screening for these compounds
In Fig. 1, while increasing the N-terminal extracellular tail
concentration (0 mM, 0.013 mM, 0.04 mM, 0.07 mM and
0.12 mM), the variance of the peak height of these compounds
was as the standard when the interaction happens. We can ﬁnd
that different compounds have the different response from
electropherograms. So the ratio between each analogs and
ML40 was different. We displayed the phenomenon of two of
these analogs for model in this ﬁgure. The concentration of the
Table 1 Reorganization of the two wings and central core.
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Z. Sun et al.266N-terminal was according to the maximum concentration,
which S009 interacted with ML40 in the previous report [18].
Compared with positive control S009, XJH-9, XJH-10, XJH-
11, XJH-12, XJH-13, XJH-14, XJH-3, XJH-8, XJH-6, XJH-7,
XJH-15, XJH-16 and XJH-2 did not bind to ML40; XJH-5,
XJH-4, XJH-17 and XJH-1 displayed the interaction with
ML40. This result shows that if the central core holds the line,
compound does not interact with ML40 when R2¼
HN
regardless of the R1’s change; when
R2¼ OCF3
H
N and R1¼ N N
H
and N
N
H
, the interaction between compounds
and ML40 happened and especially, the peak height isdecreased sharply with R1¼ N N
H
. When the
structure was ester, only the compound with
R1¼O N N
H
has the interaction with ML40. In
the series of R2¼ H
N
H3C Cl
, there was no interaction
taking place only when the central core changed into
N
O
C
C
Cl
Cl O
O
.
Figure 1 Electropherograms for compounds screening containing a ﬁxed concentration of the compound at 0.67 mM (a) and ﬁxed
concentrations of ML40 at 0.12 mM (b). The conditions used were same as follows: Beckman P/ACE MDQ capillary electrophoresis
system. Injection: 0.5 p.s.i. for 10 s. Applied voltage: 10 kV. Capillary: capillary of 30.2 cm (effective length 10 cm) 75 mm I.D. Running
buffer: 30 mM Tris–HAc, pH 7.3. The different compounds were (A) XJH-9; (B) XJH-10; the electropherograms of other compounds
were similar with the above.
Table 2 Relationship between peak height and these analogs’ concentration.
Compounds Regression equations Correlation
coefﬁcient
Concentrations (mM)
XJH-5 y¼43537x6606.3 0.9775 0.22–0.50
XJH-4 y¼319553x20126 0.9978 0.10–0.20
XJH-17 y¼107760x5162.6 0.9831 0.20–0.50
XJH-1 y¼125820xþ2797.8 0.9600 0.29–1.00
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structural modiﬁcation and structure–activity relationship.3.2. Interactions between the positivity compound and the
N-terminal extracellular tail of CCR4
To obtain a calibration plot, increasing concentrations of these
analogs were injected into the capillary, the peak heights being
proportional to the concentrations. The relationship between
peak height and these analogs concentration is expressed in
Table 2. The corresponding concentrations of the compounds in
the binding study were calculated from this calibration plot.
Fig. 2 shows electropherograms for sample alone and mixtures.
By increasing the N-terminal extracellular tail concentration the
peak height of the compounds is decreased, indicating strong
binding. Theoretically, the dissociation rate of the complex is
small and consequently it could be detected.
The binding constant is an important quantitative parameter
for characterizing the interaction between the N-terminal extra-
cellular tail of CCR4 and the compounds. The concentrationsof the free compounds were calculated from the calibration
plot to obtain the values of r and from the slope of the
Scatchard plot (Table 3), K was calculated to be XJH-5:
(1.6970.11) 105 M1; XJH-4: (3.5170.93) 104 M1; XJH-
1: (1.6070.04) 104 M1; XJH-17: (4.9470.34) 104 M1
(Table 3). The result shows that XJH-5 has the strongest afﬁnity
with the N-terminal extracellular tail and the other three
compounds also have high afﬁnity with it. Compared with the
compound action of chemotaxis inhibition potency and its
binding constant with the N-terminal extracellular tail of
CCR4 determined by CZE, we found that the compounds with
higher afﬁnity had stronger action of chemotaxis inhibition. An
attractive direction is to apply CE to high-throughput drug
screening for biological activity [19,20]. With the aid of CE,
binding constants and stoichiometry data can be obtained while
conventional drug screening techniques can only provide the
IC50 values. Our experiment shows that CE can be employed as
one of the reliable screening methods to a series of lactam
analogs in the drug discovery for allergic inﬂammation diseases
and CE can be employed to help analyze the structure–activity
relationship of compounds.
Figure 2 Electropherograms for four samples alone and mixtures containing a ﬁxed concentration of the compound at 0.67 mM and
increasing concentrations of ML40. Various concentrations of ML40: (a) 0 mM; (b) 0.013 mM; (c) 0.04 mM; (d) 0.07 mM; (e) 0.12 mM. The
conditions used were the same as Fig. 1. The different interactioned compounds were (A) XJH-5; (B) XJH-4; (C) XJH-1; (D) XJH-17.
Table 3 Compounds and the binding constants.
Compounds Regression equations Correlation
coefﬁcient
Binding constants
( 104 M1)
RSD
XJH-5 y¼14.464xþ4.8339 0.7765 16.9 0.11
XJH-4 y¼5.8123xþ0.6026 0.9795 3.51 0.93
XJH-1 y¼1.6313xþ0.4412 0.8006 1.60 0.04
XJH-17 y¼4.6579xþ2.2068 0.7621 4.94 0.34
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A series of analogs have been synthesized. Compared with positive
control S009, we screen them targeting at ML40 using CZE for
ﬁnding some new and further cell and animal experiments in the
drug discovery for allergic inﬂammation diseases. XJH-9, XJH-10,
XJH-11, XJH-12, XJH-13, XJH-14, XJH-3, XJH-8, XJH-6,
XJH-7, XJH-15, XJH-16 and XJH-2 did not bind to ML40;
XJH-5, XJH-4, XJH-17 and XJH-1 displayed the interaction with
ML40. Both qualiﬁcation and quantiﬁcation characterizations of
the binding were determined. The K values of four samples were
calculated to be XJH-5: (1.6970.11) 105 M1; XJH-4:
(3.5170.93) 104 M1; XJH1: (1.6070.04) 104 M1; XJH-
17: (4.9470.34) 104 M1 by Scatchard analysis. The afﬁnity of
the four compounds was valued by the binding constant, which
was similar with the biological experiment. Each run was
completed within 4 min. The CZE provides a highly efﬁcient,fast, quantitative and sensitive method for screening a series of
lactam analogs in the drug discovery for allergic inﬂammation
diseases. Also, our result can provide some evidence for structure–
activity relationship.Acknowledgements
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